Accepted Article

Results

Expressions of Wnt5a and Frizzled receptors during liver development

We first analyzed *Wnt5a* expression during liver development using quantitative RT-PCR. *Wnt5a* expression was detected in fetal and neonatal livers of WT mice and showed a gradual increase during liver development (Fig. 1A). To investigate Wnt5a expression in mid-gestational fetal liver, we purified the fractions of hepatoblasts, mesenchymal cells, mesothelial cells, endothelial cells, and hematopoietic cells from E14.5 liver using FACS. Quantitative RT-PCR analysis indicated that *Wnt5a* was expressed in hepatoblasts, mesenchymal cells, mesothelial cells, endothelial cells, and hematopoietic cells. The expression level of Wnt5a was significantly higher in mesenchymal cells than in hepatoblasts and other types of cells in mid-gestational fetal liver (Fig. 1B). Frizzled is a family of cell surface receptors for Wnt ligands. Adult hepatocytes from 12-week-old mice served as the control. RT-PCR analysis of E14.5 hepatoblasts resulted in detection of 9 of 10 Fzd receptors (all except *Fzd9*), whereas E14.5 hematopoietic cells expressed 9 of 10 Fzd receptors (all except *Fzd2,* Fig. 1C and supplementary Fig. 1).

Loss of Wnt5a promotes the formation of bile duct in fetal liver

Since one of the reported phenotypes of systemic Wnt5a KO mice was postpartum

Accepted Article

death[11], we investigated the function of Wnt5a in liver development using mid- to late-gestational fetuses. We determined that although average liver weight in Wnt5a KO E18.5 fetal mice was significantly lower than in WT littermates, the average ratio of liver:body weight in the KO mice was not significantly different from the ratio in WT mice (supplementary Fig. 2).

Histological analysis of E18.5 livers showed that the number of luminal spaces around the portal vein, which we interpret to be primitive bile ducts, was greater in Wnt5a KO mice than in WT mice (Fig. 2A). To further investigate these changes in bile duct development, expression of *Sox9* (a representative transcriptional factor expressed in biliary precursor cells)[20] was analyzed. Expression levels of *Sox9* were significantly higher in Wnt5a KO E16.5 fetal livers relative to WT livers (Fig. 2B). The Notch pathway plays an essential role in the morphogenesis of bile duct structures.[21] Expression levels of *Notch1*, *Notch2*, and *Jagged1* were significantly higher in Wnt5a KO E16.5 fetal livers relative to WT livers (supplementary Fig. 3A). Numbers of Hes1^{+} cells in E18.5 livers were significantly greater in Wnt5a KO mice than in WT mice (supplementary Fig. 3B). Expression levels of *Cyclin D1* and *c-Myc* (target transcripts of canonical β-catenin-dependent Wnt pathway) in Wnt5a KO livers were equal to those in WT livers (supplementary Fig. 4A). We tried to assess the protein level of Sox9, however, immunostaining analysis of Sox9 did not work well probably due to technical

problems (data not shown).

During normal liver development, hepatoblasts located around the portal vein develop as hepatocyte nuclear factor (HNF)1β^{+}HNF4α^{-} biliary precursor cells.[22] In normal E16.5 fetal livers, monolayer rings of biliary precursor cells, termed ductal plates, can be detected.[23] Two-day older WT E18.5-stage fetal livers contained primitive ductal structures (PDS) consisting of multiple HNF1β^{+}CK19^{+}-cell lumina (Fig. 2C).

Immunohistological analysis revealed that numbers of HNF1β^{+}HNF4α^{-} biliary precursor cells in E16.5 livers (Fig. 2D) and in PDS formed by these cells in E18.5 livers (Fig. 2E) were significantly higher in Wnt5a KO mice relative to WT mice. Double staining of CK19 and entactin (a component of basement membrane) confirmed that the number of PDS formed by CK19^{+} cells was also significantly higher in E18.5 Wnt5a KO liver relative to the WT (Fig. 2F). These results demonstrate clearly that loss of Wnt5a excessively promotes the formation of bile ducts in fetal liver.

Expression analysis of fetal livers in Wnt5a KO mice

Expression of genes coincident with hepatic maturation was also analyzed in Wnt5a KO fetal livers using quantitative RT-PCR. In E16.5 fetal livers, ALB and HNF4α mRNA levels were nearly equal between WT and Wnt5a KO mice. Similarly, we observed no significant differences between WT and Wnt5a KO E18.5 fetal livers

Accepted Article

with regard to copy numbers of tyrosine aminotransferase (TAT), carbamoyl phosphate synthetase 1 (CPS1), glucose-6-phosphatase (G6Pase), or HNF4α mRNAs (supplementary Figs. 5A and B). These data suggest that the maturation of hepatoblasts to hepatocytes is not impaired in Wnt5a KO mice.

Proliferation of fetal liver cells in Wnt5a KO mice was analyzed by immunoblot and immunostaining. Immunoblot analysis revealed that PCNA production in Wnt5a KO livers was almost equal to that in WT livers (supplementary Fig. 4B). Numbers of $CK19^{+}PCNA^{+}$ cells in E18.5 were almost equal to those in WT livers (supplementary Fig. 4C). Changes in gene expression in Wnt5a KO livers were analyzed using cDNA microarray analysis (supplementary Fig. 5C and supplementary Table 5). Cluster analysis revealed that several molecules associated with amino acid metabolism and cell migration were upregulated or downregulated in Wnt5a KO fetal livers compared with those in WT livers.

Wnt5a retards formation of bile duct-like structures from primary hepatoblasts

In collagen gel-embedding culture, mouse primary hepatoblasts differentiate into bile duct-like branching structures, coincident with the expression of biliary cell-specific genes such as CK19 (Fig. 3A, left panel).[6] To investigate the effects of Wnt5a on differentiation of hepatoblasts into biliary cells *in vitro*, we cultured primary

hepatoblasts derived from E14.5 WT fetal livers, and assessed the formation of bile duct-like branching structures.

We observed that cells in cultures derived from E14.5 WT fetal liver formed approximately 10 colonies (consisting of >100 cells in large branching structures) per 1×10^4 cells (Fig. 3A, right panel); colonies with medium (50-99 cells) or small (10-49 cells) branching structures also were noted. In cultures supplemented with Wnt5a, there were significant decreases in the average number colonies with large- and medium-sized branching structures relative to vehicle-only controls.

Wnt5a suppresses cyst formation derived from HPPL in three-dimensional culture

To assess the potential of hepatic stem/progenitor cells for bile-duct like luminal formation, we used an HPPL three-dimensional culture system.[19] HPPL is established from mouse E14 Dlk^+ hepatoblasts, and differentiates into hepatic and cholangiocytic lineages.[18] In this system, HPPL cells form cysts that exhibit characteristics of differentiated cholangiocytes producing CK19, E-cadherin, and other characteristic markers. We categorized HPPL-derived colonies into one of three classes: colonies without clear lumina, small cysts (50-100 μm diameter with clear lumina), and large cysts (>100 μm diameter with clear lumina). As previously described,[19] immunocytostaining of cultured cells showed that colonies without clear lumina

Accepted Article

produced both the hepatic marker ALB and the biliary marker CK19, suggesting incomplete terminal differentiation. Cells in the luminal walls of small and large cysts, in contrast, produced CK19 but not ALB, indicating their differentiation to a cholangiocyte lineage (supplementary Fig. 6). Vehicle-only controls or cultures treated with Wnt3a did not show a significant difference in overall number of cysts. In contrast, cultures supplemented with Wnt5a displayed significantly fewer cysts, due both to an absence of large cysts and a significantly reduced number of small cysts (Fig. 3B). Wnt5a is expressed in HPPL cells (supplementary Fig. 7A). We verified the specificity of effect of Wnt5a by blocking experiments. Cultures supplemented with anti-Wnt5a Ab resulted in a significant increase in numbers of HPPL-derived cysts relative to control Ab, and blocked the effects of Wnt5a supplementation (Fig. 3C). Numbers of HPPL-derived cysts were higher in cultures supplemented with Wnt5a-specific inhibitor relative to vehicle-only controls (supplementary Fig. 7B).

Immunoblot analysis indicated that CK19 production in HPPL-derived colonies were significantly down-regulated in cultured cells supplemented with Wnt5a relative to vehicle-supplemented controls, whereas the levels of ALB, AFP and PCNA did not change (Fig. 3D). Expression analysis of HPPL-derived colonies revealed that HNF1β, Notch1 and multidrug resistance-associated protein 3 (MRP3, a key primary active transporter in biliary cells) were significantly downregulated in cultured cells

Accepted Article

supplemented with Wnt5a relative to vehicle-supplemented controls (Fig. 3E). HNF1β and Sox9 were significantly upregulated in cultured cells supplemented with anti-Wnt5a Ab relative to control Ab (supplementary Fig. 7C), whereas the levels of hepatocytic markers did not change (supplementary Fig. 7D). Consistent with our *in vivo* results, these data indicate that Wnt5a suppresses bile duct-like cyst formation of fetal hepatic progenitor cells *in vitro.*

Wnt5a induces the expression of hepatic maturation markers in primary hepatoblasts in vitro

We evaluated the potential of primary hepatoblasts for hepatic maturation using an *in vitro* hepatic differentiation assay.[24] Phase-contrast microscopy after addition of EHS gel identified several morphological changes within cells, including formation of highly condensed cytosol, and clear, round nuclei typical to mature hepatocytes (Fig. 4A, middle panel). Since similar gross morphological changes were also seen in cells cultured in the presence of Wnt5a (right panel), we used quantitative RT-PCR to measure the effect of Wnt5a on expression of hepatic maturation marker genes in stem/progenitor cells. Expression of TAT and CPS1 in cultured cells increased significantly with supplemental Wnt5a (Fig. 4B), whereas changes in TO, G6Pase, and HNF4α mRNA levels were not significantly different. These results indicate that Wnt5a

contributes, in part, to primary hepatoblast maturation. Taken together, our *in vitro* data demonstrate that Wnt5a retards biliary differentiation and promotes hepatic differentiation of hepatoblasts.

Inhibition of CaMKII activity promotes the formation of bile-duct like cysts derived from HPPL

While Wnt5a is known to stimulate several signaling cascades, including CaMKII, Rho-kinase, Rac1, Calcineurin, and PKC, the specific cascade triggered by Wnt5a in hepatic stem/progenitor cells is unknown. To address this question, we analyzed the effects of specific inhibitors of these candidate molecules in HPPL-derived cysts, where Wnt5a is expressed (Supplementary Fig. 7A). Relative to controls, inhibitors specific to CaMKII (KN93 and KN62) resulted in a significant increase in numbers of both small and large bile-duct like cysts derived from HPPL (Figs. 5A and 5B). In contrast, other inhibitors, including Y-27632 (Rho-kinase inhibitor), NSC23766 (Rac1 inhibitor), Cyclosporin A (Calcineurin inhibitor) and Go6976 (PKC inhibitor), had no effect on the number or size of HPPL-derived cysts (Fig. 5C). We examined the expression of biliary markers in HPPL-derived cysts treated with CaMKII inhibitor (KN62). Expression of MRP3, a key primary active transporter in biliary cells, in HPPL-derived cysts increased significantly with supplemental CaMKII inhibitor (Fig. 5D). There were

no significant differences in mRNA levels of ALB, HNF4α, and β-catenin-related molecules between HPPL-derived cysts treated with CaMKII inhibitor and those treated with vehicle (supplementary Fig. 8). The protein level of AFP in HPPL-derived cysts treated with CaMKII inhibitor was lower than that in vehicle-supplemented controls, whereas the levels of CK19 and PCNA did not change (Fig. 5E). These data indicate that CaMKII activity suppresses the formation of HPPL-derived cysts, whereas activities of other Wnt5a-mediated candidates did not influence the efficacy of cyst formation.

Phosphorylation of CaMKII in primary hepatoblasts

To investigate the activation state of CaMKII in fetal and neonatal WT livers, we used immunoblots of liver homogenates derived from E14.5, E16.5, E18.5, postnatal day (P) 1, P7, and P14 mice to measure CaMKII phosphorylation levels. Phosphorylation at threonine-286, specifically, has been reported to maintain CaMKII in an active state.[25] Phosphorylation of PKC, a kinase that did not affect cyst formation in HPPL cells, was also examined. While we detected both phosphorylated CaMKII (p-CaMKII) and PKC (p-PKC) in each fetal and neonatal liver homogenate, levels of phosphorylated CaMKII increased gradually over time (supplementary Fig. 9A, top panel), similar to the pattern of Wnt5a expression during liver development (Fig. 1A).

Accepted Article

Accepted Article

In contrast, developmental changes in the steady-state levels and phosphorylation of PKC in these samples (supplementary Fig. 9A, lower panels) did not correspond to Wnt5a expression patterns.

Using immunostaining of FACS-purified primary hepatoblasts with anti p-CaMKII Ab, we detected p-CaMKII in >90% of FACS-purified primary hepatoblasts (supplementary Fig. 9B, upper panels); p-PKC was also detected with anti p-PKC antibodies in these cells (supplementary Fig. 9B, lower panels). These data demonstrate that both CaMKII and PKC are in an active state in primary hepatoblasts.

Wnt5a regulates the phosphorylation of CaMKII in fetal liver

To verify whether CaMKII activation is controlled by Wnt5a, levels of p-CaMKII in HPPL grown in the absence or presence of Wnt5a were examined. Immunoblot analysis showed that Wnt5a stimulation increased the level of phosphorylated CaMKII, with p-CaMKII levels peaking 3 hours after Wnt5a supplementation and then decreasing to baseline levels after 12 hours (Fig. 6A and supplementary Fig. 10A). Similar to a previous report,[15] total CaMKII protein levels in HPPL also increased after CaMKII activation. Ratios of p-CaMKII/CaMKII also increased, peaking 3 hours after Wnt5a supplementation (supplementary Fig. 10B). In contrast, Wnt5a had no effect on p-PKC and p-Rac1 levels in HPPL (supplementary Figs. 10C and D) nor on

nuclear translocation of NFAT (representative downstream molecule of Calcineurin; data not shown).

We also tested the combined effect of Wnt5a plus a CaMKII inhibitor (KN62) on cyst formation in HPPL-derived cells. The number and size of cysts in HPPL-derived cells decreased with Wnt5a alone, and increased with CaMKII inhibitor alone. When used in combination (HPPL treated with both CaMKII inhibitor plus Wnt5a), the number and size of cysts was similar to CaMKII inhibitor alone, and significantly higher than cells treated with Wnt5a alone (Fig. 6B and C).

We also used immunoblots to compare p-CaMKII levels in WT and Wnt5a KO fetal liver homogenates. Levels of p-CaMKII were significantly lower in Wnt5a KO relative to WT fetal livers (Fig. 6D); quantification using densitometry revealed that p-CaMKII levels in Wnt5a KO livers were also significantly lower than those in littermate WT livers (supplementary Fig. 10E), indicating that Wnt5a mediates an increase in CaMKII phosphorylation in fetal liver.

Accepted Article

Accepted Article

Discussion

This study provides the first evidence of a physiological role for Wnt5a in liver development, in that Wnt5a was observed to suppress the formation of bile ducts derived from hepatoblasts. Our data showed increased expression of Sox9, Notch1, Notch2, and Jagged1 in Wnt5a KO livers (Fig. 2B and supplementary Fig. 3A), as well as abnormally increased formation of primitive ductal structures (Fig. 2E and F). In Wnt5a KO livers, the numbers of HNF1β^{+}HNF4α^{-} biliary precursor cells and primitive ductal structures were increased around the portal vein only (zone 1), whereas such cells were not observed in zone 2 or 3 (Fig. 2D-F). At E14.5 stage, HNF1β^{+}HNF4α^{-} biliary precursor cells were not detected in Wnt5a KO livers similar to WT livers (supplementary Fig. 11A). These results suggested that lineage commitment of hepatoblasts into biliary cells is determined by the microenvironment around the portal vein, depending on the presence or absence of Wnt5a protein. The lung and intestine of systemic Wnt5a KO were abnormal, while tissue structures of pancreas and kidney were almost normal (supplementary Fig. 12). Immunostaining analysis showed that p75NTR^{+} cells were detected in E18.5 Wnt5a KO livers, similar to WT livers (supplementary Fig. 11B). These results implied that development of mesenchymal cells in E18.5 Wnt5a KO livers is not impaired compared with that in littermate WT livers. Wnt5a expression was significantly higher in mesenchymal cells than in

hepatoblasts or other types of cells in mid-gestational WT fetal liver (Fig. 1B). Thus, the microenvironment around the portal vein, which consists of mesenchymal cells, other types of cells, and extracellular matrices, regulates appropriate cell fate decision of hepatoblasts, whereas loss of Wnt5a in such developmental niche leads to abnormally increased formation of primitive ductal structures (Fig. 7). Further investigation of this hypothesis will require conditional deletion of Wnt5a-downstream molecules in hepatoblasts at late-gestational fetal stages.

Maturation of hepatoblasts to a hepatocyte lineage is regulated by several factors, including oncostatin M, HGF, and extracellular matrices.[24] Our data showed that hepatic maturation of primary hepatic stem/ progenitor cells was promoted in cultures supplemented with Wnt5a (Fig. 4A and B). On the other hand, no significant changes in hepatocyte-marker expression were detected in Wnt5a KO relative to WT livers. It may be that there is functional redundancy among different Wnt-family ligands *in vivo*, since several non-canonical-signaling Wnt ligands (Wnt4, Wnt5a, and Wnt11) are expressed in normal fetal liver.[26] In support of the hypothesis that other non-canonical Wnt ligands may compensate for Wnt5a, supplementary Figure 13A shows that Wnt4 expression levels in liver increase significantly in Wnt5a KO versus WT littermates. These data strongly support our hypothesis that the effect of Wnt5a on hepatic maturation is

Accepted Article

compensated by other non-canonical Wnt ligands, such as Wnt4.

CaMKII, a serine/threonine protein kinase present in essentially every tissue, regulates important functions including modulation of ion channel activity, cellular transport, and cell morphology in neural tissues.[27] A Wnt5a-CaMKII pathway has been reported to induce osteoblastogenesis by attenuating adipogenesis in mesenchymal bone marrow stem cells.[15] Our results show that in liver, inhibition of CaMKII activity promoted bile duct-like cyst formation (Fig. 5A and B), and that phosphorylation of CaMKII is dependent on Wnt5a stimulation (Fig. 6). While these results provide strong support to our hypothesis that Wnt5a stimulates CaMKII in hepatoblasts, we have not identified which molecules function downstream of CaMKII.

CaMKII has been reported to activate the TGFβ-activated kinase 1(TAK1)-Nemo-like kinase (NLK) pathway, and that resulting phosphorylation of TCF inhibits β-catenin dependent transcription.[28] On the other hand, CaMKII-TAK1-NLK signaling induces bone-marrow mesenchymal stem cells to undergo osteoblastogenesis depending on specific downstream signaling cascades.[15] Our expression analysis showed that expression levels of *Cyclin D1* and *c-Myc* (the direct target molecules of β-catenin activation) did not change in Wnt5a KO mice *in vivo* (supplementary Fig. 4) nor in HPPL-derived cysts treated with CaMKII inhibitor *in vitro* (supplementary Fig. 8), compared with the respective control samples. Preliminary data (not shown)

Accepted Article

Accepted Article

demonstrated that the levels of TAK1 mRNA and protein during development did not correlate with those of Wnt5a and p-CaMKII in whole liver lysates. Moreover, Wnt5a stimulation did not increase the level of activated β-catenin in HPPL (supplementary Fig. 13B and C). These results suggest that the Wnt5a-CaMKII pathway does not activate β-catenin in hepatoblasts. On the other hand, Wnt5a stimulation increased the level of stabilized p53 (phosphorylated at Ser15) in HPPL (supplementary Fig. 13B and D), suggesting that stabilization of p53 is associated with Wnt5a-CaMKII signaling. Further study will be needed to clarify this issue.

Recent studies have shown pathological roles for Wnt5a in various organs: Addition of recombinant Wnt5a significantly reduced the migratory capacity of colorectal cancer cell line.[29] Whereas increased Wnt5a expression correlates with advanced stages of gastric cancer with poor prognosis,[30] there is no definitive data about Wnt5a in the progression of hepatocellular carcinomas. In this study, we reveal one function of Wnt5a in fetal liver in the suppression the biliary differentiation of hepatic stem/progenitor cells. To clarify the pathological role of Wnt5a in liver disease, inducible systemic Wnt5a KO mice or liver-specific CaMKII KO mice would be needed in future studies. Any future evidence demonstrating a role for Wnt5a in adult hepatic stem/progenitor cells and cancer stem cells may lead to studies of Wnt5a signaling as a therapeutic target against abnormal bile ductal formation in the liver or

cholangiocellular carcinoma.

Accepted Article

References

1. Turner R, Lozoya O, Wang Y, Cardinale V, Gaudio E, Alpini G, Mendel G, et al. Human hepatic stem cell and maturational liver lineage biology. Hepatology 2011;53:1035-1045.

2. Cardinale V, Wang Y, Carpino G, Cui CB, Gatto M, Rossi M, Berloco PB, et al. Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology 2011;54:2159-2172.

3. Kubota H, Reid LM. Clonogenic hepatoblasts, common precursors for hepatocytic and biliary lineages, are lacking classical major histocompatibility complex class I antigen. Proc Natl Acad Sci USA 2000;97:12132-12137.

4. Kakinuma S, Ohta H, Kamiya A, Yamazaki Y, Oikawa T, Okada K, Nakauchi H. Analyses of cell surface molecules on hepatic stem/progenitor cells in mouse fetal liver. J Hepatol 2009;51:127-138.

5. Zhou H, Rogler LE, Teperman L, Morgan G, Rogler CE. Identification of hepatocytic and bile ductular cell lineages and candidate stem cells in bipolar ductular reactions in cirrhotic human liver. Hepatology 2007;45:716-724.

6. Oikawa T, Kamiya A, Kakinuma S, Zeniya M, Nishinakamura R, Tajiri H, Nakauchi H. Sall4 Regulates Cell Fate Decision in Fetal Hepatic Stem/Progenitor Cells. Gastroenterology 2009;136:1000-1011.

Accepted Article

Accepted Article

7. Suzuki A, Sekiya S, Buscher D, Belmonte JCI, Taniguchi H. Tbx3 controls the fate of hepatic progenitor cells in liver development by suppressing p19(ARF) expression. Development 2008;135:1589-1595.

8. van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009;136:3205-3214.

9. Kikuchi A, Yamamoto H, Sato A, Matsumoto S. Wnt5a: its signalling, functions and implication in diseases. Acta Physiol (Oxf)2012;204:17-33.

10. Tan XP, Yuan YZ, Zeng G, Apte U, Thompson MD, Cieply B, Stolz DB, et al. beta-catenin deletion in hepatoblasts disrupts hepatic morphogenesis and survival during mouse development. Hepatology 2008;47:1667-1679.

11. Yamaguchi TP, Bradley A, McMahon AP, Jones S. A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development 1999;126:1211-1223.

12. Li CG, Xiao J, Hormi K, Borok Z, Minoo P. Wnt5a participates in distal lung morphogenesis. Dev Biol 2002;248:68-81.

13. Cervantes S, Yamaguchi TP, Hebrok M. Wnt5a is essential for intestinal elongation in mice. Dev Biol 2009;326:285-294.

14. Nemeth MJ, Topol L, Anderson SM, Yang YZ, Bodine DM. Wnt5a inhibits canonical Wnt signaling in hematopoietic stem cells and enhances repopulation. Proc

Accepted Article

Natl Acad Sci USA 2007;104:15436-15441.

15. Takada I, Mihara M, Suzawa M, Ohtake F, Kobayashi S, Igarashi M, Youn M, et al. A histone lysine methyltransferase activated by non- canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol 2007;9:1273-1285.

16. Parish CL, Castelo-Branco G, Rawal N, Tonnesen J, Sorensen AT, Salto C, Kokaia M, et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest 2008;118:149-160.

17. Zeng G, Awan F, Otruba W, Muller P, Apte U, Tan XP, Gandhi C, et al. Wnt'er in liver: Expression of Wnt and frizzled genes in mouse. Hepatology 2007;45:195-204.

18. Tanimizu N, Saito H, Mostov K, Miyajima A. Long-term culture of hepatic progenitors derived from mouse Dlk+ hepatoblasts. J Cell Sci 2004;117:6425-6434.

19. Tanimizu N, Miyajima A, Mostov KE. Liver progenitor cells develop cholangiocyte-type epithelial polarity in three-dimensional culture. Mol Biol Cell 2007;18:1472-1479.

20. Antoniou A, Raynaud P, Cordi S, Zong Y, Tronche F, Stanger BZ, Jacquemin P, et al. Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology 2009;136:2325-2333.

21. Lozier J, McCright B, Gridley T. Notch signaling regulates bile duct morphogenesis in mice. PLoS One 2008;3:e1851.

22. Tchorz JS, Kinter J, Muller M, Tornillo L, Heim MH, Bettler B. Notch2 signaling promotes biliary epithelial cell fate specification and tubulogenesis during bile duct development in mice. Hepatology 2009;50:871-879.

23. Si-Tayeb K, Lemaigre FP, Duncan SA. Organogenesis and development of the liver. Dev Cell 2010;18:175-189.

24. Kamiya A, Kojima N, Kinoshita T, Sakai Y, Miyaijma A. Maturation of fetal hepatocytes in vitro by extracellular matrices and oncostatin M: induction of tryptophan oxygenase. Hepatology 2002;35:1351-1359.

25. Patton BL, Molloy SS, Kennedy MB. Autophosphorylation of type II CaM kinase in hippocampal neurons: localization of phospho- and dephosphokinase with complementary phosphorylation site-specific antibodies. Mol Biol Cell 1993;4:159-172.

26. Konishi S, Yasuchika K, Ishii T, Fukumitsu K, Kamo N, Fujita N, Ikai I, et al. A transmembrane glycoprotein, gp38, is a novel marker for immature hepatic progenitor cells in fetal mouse livers. In Vitro Cell Dev Biol Anim 2011;47:45-53.

27. Yamauchi T. Neuronal Ca2+/calmodulin-dependent protein kinase II - Discovery, progress in a quarter of a century, and perspective: Implication for learning and memory. Biol Pharm Bull 2005;28:1342-1354.

28. Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J, Waterman M, Shibuya H, et al. The TAK1-NLK mitogen-activated protein kinase cascade functions in

Accepted Article